NERV Minerva Neurosciences, Inc.
Minerva Neurosciences, Inc. (NERV) is expected to report earnings on November 6, 2026, before the market open. The consensus earnings estimate is a loss of $0.14 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +4.3% since its last earnings release on August 7, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Minerva Neurosciences, Inc.
Minerva Neurosciences Inc is a development stage bio-pharmaceutical company. It develops experimental drugs for the treatment of schizophrenia, insomnia and Parkinson' disease.
Sector
Healthcare
Industry
Biotechnology